Compare Stocks: ATRA, ORIC, IRD, and SRZN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$8.09 -4.9%	$9.40	$3.92 ▼ $19.15	$72.89M	0.12	55,414 shs	66,247 shs
IRD Opus Genetics	$3.61 -3.0%	$3.76	$1.10 ▼ $5.81	$298.36M	0.59	843,325 shs	414,229 shs
ORIC Oric Pharmaceuticals	$13.87 +1.1%	$10.72	$7.23 ▼ $14.93	$1.44B	1.02	1.70 million shs	828,503 shs
SRZN Surrozen	$23.96 +1.0%	$22.94	$10.11 ▼ $35.00	$278.18M	0.52	287,071 shs	212,866 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	0.00%	-4.26%	-7.22%	-15.55%	-33.31%
IRD Opus Genetics	0.00%	-1.37%	+10.06%	-24.79%	+228.18%
ORIC Oric Pharmaceuticals	0.00%	+2.74%	+29.26%	+70.18%	+41.10%
SRZN Surrozen	0.00%	-6.48%	+15.47%	-14.88%	+138.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$8.09 -4.9%	$9.40	$3.92 ▼ $19.15	$72.89M	0.12	55,414 shs	66,247 shs
IRD Opus Genetics	$3.61 -3.0%	$3.76	$1.10 ▼ $5.81	$298.36M	0.59	843,325 shs	414,229 shs
ORIC Oric Pharmaceuticals	$13.87 +1.1%	$10.72	$7.23 ▼ $14.93	$1.44B	1.02	1.70 million shs	828,503 shs
SRZN Surrozen	$23.96 +1.0%	$22.94	$10.11 ▼ $35.00	$278.18M	0.52	287,071 shs	212,866 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	0.00%	-4.26%	-7.22%	-15.55%	-33.31%
IRD Opus Genetics	0.00%	-1.37%	+10.06%	-24.79%	+228.18%
ORIC Oric Pharmaceuticals	0.00%	+2.74%	+29.26%	+70.18%	+41.10%
SRZN Surrozen	0.00%	-6.48%	+15.47%	-14.88%	+138.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.00	Hold	$9.50	17.43% Upside
IRD Opus Genetics	2.89	Moderate Buy	$10.69	196.19% Upside
ORIC Oric Pharmaceuticals	2.80	Moderate Buy	$19.45	40.26% Upside
SRZN Surrozen	2.67	Moderate Buy	$42.00	75.29% Upside

Current Analyst Ratings Breakdown

Latest ATRA, ORIC, IRD, and SRZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	IRD Opus Genetics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/10/2026	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $27.00
8/10/2026	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$44.00
8/7/2026	IRD Opus Genetics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$10.00 ➝ $9.00
7/31/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	IRD Opus Genetics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/28/2026	SRZN Surrozen	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/17/2026	IRD Opus Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ORIC Oric Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	SRZN Surrozen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$120.77M	0.60	$4.87 per share	1.66	($5.34) per share	-1.51
IRD Opus Genetics	$14.20M	21.01	N/A	N/A	$0.22 per share	16.41
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.90 per share	N/A
SRZN Surrozen	$3.48M	79.94	N/A	N/A	($19.21) per share	-1.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	$32.69M	-$1.18	N/A	5.78	N/A	-269.42%	-79.12%	-73.01%	10/29/2026 (Estimated)
IRD Opus Genetics	-$49.59M	-$1.35	N/A	N/A	N/A	-1,091.82%	-338.88%	-150.13%	N/A
ORIC Oric Pharmaceuticals	-$129.47M	-$1.35	N/A	N/A	N/A	N/A	-35.35%	-33.39%	N/A
SRZN Surrozen	-$242.03M	-$40.55	N/A	N/A	N/A	-2,885.33%	N/A	-93.62%	N/A

Latest ATRA, ORIC, IRD, and SRZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ATRA Atara Biotherapeutics	-$0.3150	-$0.32	-$0.0050	-$0.32	$0.55 million	$0.63 million
8/6/2026	Q2 2026	IRD Opus Genetics	-$0.1567	-$0.14	+$0.0167	-$0.14	$2.63 million	$0.76 million
8/6/2026	Q2 2026	SRZN Surrozen	-$1.29	-$0.41	+$0.88	-$0.41	$0.47 million	$5.00 million
8/3/2026	Q2 2026	ORIC Oric Pharmaceuticals	-$0.3594	-$0.38	-$0.0207	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	1.98	1.98
IRD Opus Genetics	N/A	12.19	12.19
ORIC Oric Pharmaceuticals	N/A	13.19	13.19
SRZN Surrozen	N/A	12.14	12.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
IRD Opus Genetics	14.97%
ORIC Oric Pharmaceuticals	95.05%
SRZN Surrozen	66.57%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	41.20%
IRD Opus Genetics	11.70%
ORIC Oric Pharmaceuticals	5.70%
SRZN Surrozen	31.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	9.01 million	5.30 million	No Data
IRD Opus Genetics	14	82.65 million	72.98 million	N/A
ORIC Oric Pharmaceuticals	80	103.65 million	97.75 million	Optionable
SRZN Surrozen	80	11.61 million	7.93 million	Not Optionable

ATRA, ORIC, IRD, and SRZN Headlines

Recent News About These Companies

What is HC Wainwright's Forecast for Surrozen Q3 Earnings?

August 14 at 1:28 AM | americanbankingnews.com

What is HC Wainwright's Estimate for Surrozen Q3 Earnings?

August 12, 2026 | marketbeat.com

HC Wainwright Reaffirms Buy Rating for Surrozen (NASDAQ:SRZN)

August 12, 2026 | americanbankingnews.com

HC Wainwright Reiterates "Buy" Rating for Surrozen (NASDAQ:SRZN)

August 10, 2026 | marketbeat.com

Surrozen (NASDAQ:SRZN) Issues Quarterly Earnings Results, Beats Expectations By $0.88 EPS

August 6, 2026 | marketbeat.com

Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | globenewswire.com

Perceptive Advisors LLC Makes New $6.68 Million Investment in Surrozen, Inc. $SRZN

August 2, 2026 | marketbeat.com

Surrozen, Inc. (NASDAQ:SRZN) Given Consensus Rating of "Moderate Buy" by Brokerages

July 30, 2026 | marketbeat.com

Surrozen, Inc. $SRZN Position Reduced by Stempoint Capital LP

July 30, 2026 | marketbeat.com

Surrozen (NASDAQ:SRZN) Upgraded by Zacks Research to Hold Rating

July 30, 2026 | marketbeat.com

Surrozen (NASDAQ:SRZN) Major Shareholder Sells $6,906,250.00 in Stock

July 29, 2026 | insidertrades.com

Surrozen Inc

July 28, 2026 | edition.cnn.com

Insider Selling: Surrozen (NASDAQ:SRZN) Major Shareholder Sells 325,000 Shares of Stock

July 28, 2026 | marketbeat.com

Surrozen highlights Wnt retina pipeline, SZN-8141 IND timeline at HC Wainwright

July 22, 2026 | msn.com

Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright

July 22, 2026 | marketbeat.com

Surrozen to Present at Upcoming Healthcare Investor Conference

July 15, 2026 | globenewswire.com

Surrozen (SRZN) Stock Forecast & Price Target

June 4, 2026 | investing.com

We're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Rate

May 17, 2026 | finance.yahoo.com

Surrozen (SRZN) price target increased by 10.11% to 43.52

May 14, 2026 | msn.com

Surrozen Shareholders Support Board, Auditor and Pay Policies

May 14, 2026 | tipranks.com

Surrozen to Present at Upcoming Healthcare Investor Conference

May 12, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATRA, ORIC, IRD, and SRZN Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$8.09 -0.42 (-4.94%)

As of 08/14/2026 04:00 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Opus Genetics NASDAQ:IRD

$3.61 -0.11 (-2.96%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.67 +0.06 (+1.66%)

As of 08/14/2026 07:34 PM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Oric Pharmaceuticals NASDAQ:ORIC

$13.87 +0.15 (+1.09%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$13.64 -0.23 (-1.62%)

As of 08/14/2026 07:49 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Surrozen NASDAQ:SRZN

$23.96 +0.23 (+0.97%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$23.92 -0.05 (-0.19%)

As of 08/14/2026 04:10 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATRA, ORIC, IRD, and SRZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATRA, ORIC, IRD, and SRZN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATRA, ORIC, IRD, and SRZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATRA, ORIC, IRD, and SRZN Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Opus Genetics NASDAQ:IRD

Oric Pharmaceuticals NASDAQ:ORIC

Surrozen NASDAQ:SRZN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATRA, ORIC, IRD, and SRZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATRA, ORIC, IRD, and SRZN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATRA, ORIC, IRD, and SRZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATRA, ORIC, IRD, and SRZN Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Opus Genetics NASDAQ:IRD

Oric Pharmaceuticals NASDAQ:ORIC

Surrozen NASDAQ:SRZN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools